BIOCORP
27.9.2021 06:47:07 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today announces an agreement with Novo Nordisk, a world leader in diabetes care, for the development and distribution (pending successful development) of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes.
Mallya is a Bluetooth enabled smart add-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software. Mallya helps people with diabetes maintain a reliable dose log, using technology to help improve understanding and allowing people to dose with confidence.
Most Novo Nordisk's insulins are offered with the FlexTouch pen, and it is part of the launch map for all new insulins. A specific version of Mallya will be developed for FlexTouch, the first prefilled insulin delivery device with no-push-button extension. Due to the unique dosing mechanism of FlexTouch, the push button does not extend at any dose and allows insulin to be administered by pressing the low injection force button. The existing Mallya device had to be redesigned to meet the needs of this mechanism, keeping its accuracy and reliability for the patient.
Directly attached on the disposable pre-filled FlexTouch pen, Mallya will allow seamless and efficient dose logging on FlexTouch, which could help people with diabetes and their HCPs to have more personalized conversations about the disease and treatment compliance.
Biocorp will receive an upfront payment and different milestones are defined staging the development phase. Upon successful development, Novo Nordisk plans to distribute the smart device in selected countries, and Biocorp expects to ramp up production volumes from 2022. Financials and terms of contract are not disclosed.
“Novo Nordisk collaborates with Biocorp as we believe people with diabetes deserve the freedom to decide which solution works best for them. Our Swedish study1 demonstrates the health benefits associated with the use of smart insulin pens. And as we continue launching such smart pens, we also partner with Biocorp to allow even more people with diabetes to reap the benefits connected devices can provide. This collaboration demonstrates our commitment to making diabetes management easier by giving people access to data on medication usage behaviour which is known to potentially result in improved patient outcomes”, said Søren Smed Østergaard, vice president of Digital Health at Novo Nordisk.
“Biocorp is very proud to sign this partnership with the world's leading diabetes company, Novo Nordisk, and it is a huge recognition for our Mallya. Providing almost 50% of the insulin used worldwide, Novo Nordisk distributed more than 500 million insulin pens in 2020, treating close to 30 million patients. The FlexTouch pen is not concerned by Mallya's current version, while used by tens of millions of patients with diabetes in the world, so we are pleased to be working to open up the possibilities of connectivity for the many patients around the world who use this pen. ”, said Éric Dessertenne, CEO of BIOCORP.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com .
1 “Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen ”, Diabetes Technology & Therapeutics, Vol: 22(7), 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210926005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Moody’s Corporation Elects Keith Demmings to Board of Directors12.8.2026 22:15:00 CEST | Press release
Moody’s Corporation (NYSE:MCO) today announced that Keith Demmings has been elected to the Company’s Board of Directors, effective November 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812902420/en/ Mr. Demmings, 54, currently serves as President and Chief Executive Officer of Assurant, Inc., a publicly traded company that safeguards and services connected devices, homes, automobiles, and commercial equipment in partnership with the world’s leading brands, a position he has held since January 2022. He has also served on Assurant’s Board of Directors since that time. Prior to his appointment as Chief Executive Officer, Mr. Demmings served as President of Assurant from 2021 to 2022, overseeing all operating segments, including Global Lifestyle and Global Housing. Earlier, he served as Executive Vice President and President, Global Lifestyle from 2016 to 2021, Executive Vice President and President, Global Markets
Lattice to Deliver Keynote at 2026 OCP Global Summit12.8.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that Lattice will deliver a keynote at the 2026 OCP Global Summit. Ford Tamer, President and CEO of Lattice Semiconductor, will take the stage with Sanjoy Maity, Senior Vice President, AMI Business Unit Leader, Lattice Semiconductor. Together, they will discuss the growing need for a common management and control model for AI and compute infrastructure, and how the OCP Community can work together to bring this vision to life with existing open technologies. The keynote will take place on Tuesday, Oct. 13, 2026, at 10 a.m. PT at the San Jose Convention Center (SJCC), South Hall, San Jose, California. The OCP Summit is the premier event uniting the most forward-thinking minds in open IT Ecosystem development. The Summit presents a unique platform for the OCP community from around the globe to share their insights, foster partnerships, and showcase cutting-edge advancements in op
BM3EAC Corp. 2026 Semi-Annual Report12.8.2026 17:51:00 CEST | Press release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2026 to 30 June 2026. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER The Company’s semi-annual report referenced in this announcement may include forward-looking statements, which are based on the Company's current expectations and projections regarding a business combination, the business, the economy and other future conditions of the Company and speak only as of the date hereof. Forward-looking statements may
STL Selects Kinaxis Planning One to Strengthen Supply Chain Planning Across Global Operations12.8.2026 16:10:00 CEST | Press release
Deployment reflects Kinaxis' continued investment in India and expanding access through its growing partner ecosystem Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that STL (NSE: STLTECH), a leading optical and digital solutions company, has selected Kinaxis Planning One to strengthen its supply chain planning capabilities and improve decision-making speed across its global operations. The deployment reflects Kinaxis' continued commitment to the Indian market and represents another milestone in expanding customer access through its growing network of value-added reseller (VAR) partners, and its first customer win through the company's Google Marketplace mid-market initiative. "Manufacturers are under increasing pressure to respond to volatility with faster, more coordinated decisions," said Ray Curbelo, SVP, Global Partner Organization at Kinaxis. "This engagement with STL reflects both the growing demand for modern supply chain planning in Ind
Azalea Vision Appoints Co-Founder Andrés Vasquez Quintero as Chief Executive Officer to Lead Next Phase of Clinical Development12.8.2026 16:00:00 CEST | Press release
Co-founder Andrés Vasquez Quintero assumes the CEO role while continuing as Chief Technology Officer, ensuring leadership continuity. Leadership transition positions Azalea Vision for clinical development of its smart contact lens platform, following selection for the EIC Accelerator. Co-founder Enrique Vega transitions to the Board of Directors, preserving founder continuity. Azalea Vision, a Belgian healthtech company, today announced that co-founder and CTO Andrés Vasquez Quintero will become Chief Executive Officer, effective immediately, while continuing as CTO. The transition marks the company’s next phase, advancing its smart contact lens platform into clinical development, following its selection for the European Innovation Council (EIC) Accelerator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812586109/en/ Andrés Vásquez Quintero, CEO & CTO of Azalea Vision As the inventor of Azalea Vision’s proprietary adapti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom